<DOC>
	<DOCNO>NCT01453296</DOCNO>
	<brief_summary>This study investigate effect dose paedeatric asthmatic subject GW642444 , orally inhale long-acting agonist β2-adrenoceptor .</brief_summary>
	<brief_title>Pharmacokinetics Pharacodynamics GW642444 Paedetric Subjects</brief_title>
	<detailed_description>This study investigate effect dose 25 μg GW642444 , orally inhale long-acting agonist β2-adrenoceptor , asthmatic subject age 5 11 . GW642444 currently development long-acting beta-agonist component combination product contain inhaled corticosteroid longacting beta-agonist . Subjects receive single dose via novel dry powder inhaler , 7 day once-daily repeat dose follow washout period . The study randomize two-way crossover , placebo control . Approximately 26 subject recruit study , aim 20 complete study . Safety , tolerability , pharmacokinetics glucose potassium level investigate .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male premenarchial female subject age 511 year last planned treatment day eligible study . Premenarchial female define female yet begin menses consider Tanner Stage 2 less . Diagnosis asthma least 6 month prior screen . Patients must control exist asthma treatment Screening define Childhood Asthma Control Test score &gt; 19 PEF ( Peak Expiratory Flow ) &gt; 75 % predict . Subjects must take stable regimen fluticasone propionate ( ≤200 μg ( microgram ) twice daily equivalent ) short act betaagonist inhaler asneed basis least 4 week prior screen . Apart asthma , eczema rhinitis , subject healthy suffer significant medical condition . Subjects must weigh least 15 kg ( kilogram ) . Subjects must demonstrate ability accept effectively use GW642444 device use demonstration kit provide site . The subject parent guardian able understand comply protocol requirement , instruction , protocolstated restriction . The parent guardian must ability read , write record diary information collect throughout study . The parent guardian must also ability manage study drug administration PEF assessment . At least one parent guardian sign date write informed consent prior admission study . This accompany informed assent subject . Subjects currently receive ( receive within 4 week screen ) follow asthma therapy : theophylline , longacting inhaled betaagonists , oral betaagonist . Subjects change asthma medication within 4 week screen . Clinical visual evidence oral candidiasis screen . Any clinically relevant abnormality identify screen medical assessment Any medical condition circumstance make subject unsuitable participation study ( e.g . history lifethreatening asthma ) Asthma exacerbation require systemic corticosteroid ( oral , intramuscular , intravenous ) Emergency Room attendance within 3 month asthma exacerbation require hospitalization within 6 month prior screen visit . Culturedocumented suspected bacterial viral infection upper low respiratory tract resolve within 4 week screen visit . Any adverse reaction include immediate delay hypersensitivity betaagonist therapy . Known suspected sensitivity constituent novel dry powder inhaler ( i.e. , lactose magnesium stearate ) , example , history severe milk protein allergy . The parent guardian history psychiatric disease , intellectual deficiency , substance abuse , condition ( e.g. , inability read , comprehend write ) limit validity consent participate study . A subject eligible study he/she immediate family member participate Investigator , subInvestigator , study coordinator , employee participate Investigator . Children ward state government . Evidence clinically significant abnormality 12lead ECG ( electrocardiogram ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GW642444</keyword>
</DOC>